HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: a systematic review and meta-analysis

Breast cancer (BC) with overexpression and/or amplification of the Human Epidermal Growth Factor Receptor 2 (HER2-positive) represents 11-30% of all breast tumors[1]. HER2 positivity is defined today by immunohistochemistry (IHC) as complete and strong membrane staining (i.e. score of 3+) in ≥10% of cancer cells, and/or by in situ immunofluorescence (ISH) techniques as amplified using a HER2/CEP17 ratio cutoff of ≥ 2.0 and an average HER2 gene copy number ≥ 4.0 signals per cell[2]. This consensus definition is based on the methods and cutoffs used over the years in pivotal trials that led to the approval of trastuzumab[3], pertuzumab[4], neratinib[5], lapatinib[6] and T-DM1[7] in HER2+ breast cancer.
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Systematic or Meta-analysis Studies Source Type: research

Related Links:

Authors: Zambelli A, Pappagallo G, Marchetti P Abstract Aim: Adding pertuzumab to standard trastuzumab-based adjuvant therapy significantly improved invasive disease-free survival (IDFS) in the APHINITY trial. However, the magnitude of benefit was marginal in the overall population. Methods: We used GRADE (Grading of Recommendations Assessment, Development and Evaluation) analysis on data from APHINITY to build summary-of-findings tables to evaluate the efficacy, safety and quality of evidence of predefined clinical outcomes for the addition of pertuzumab to trastuzumab-based adjuvant therapy in patients with high-...
Source: Journal of Comparative Effectiveness Research - Category: General Medicine Tags: J Comp Eff Res Source Type: research
ConclusionPharmacokinetic quantitative parameters with histogram and texture features obtained from DCE-MRI are associated with the molecular subtypes of breast cancer, and may serve as potential imaging biomarkers to differentiate between the luminal A and luminal B molecular subtypes.
Source: Academic Radiology - Category: Radiology Source Type: research
ConclusionesLa colocación de semillas de 125I es una técnica factible para la localización intraoperatoria del ganglio positivo biopsiado en combinación con la BGC. El resultado anatomopatológico del GM permite determinar el estatus axilar posneoadyuvancia.AbstractObjectiveTo present our initial experience in the combined procedure of intraoperative detection of axillary positive node marked with 125I seed (ML) and sentinel node biopsy (SLN) after neoadjuvant chemotherapy (NACT), in breast cancer patients.Material and methodsProspective study, January 2017 – March 2019, 16 breast ca...
Source: Revista Espanola de Medicina Nuclear e Imagen Molecular - Category: Nuclear Medicine Source Type: research
Brain metastasis (BM) predominantly occurs in triple-negative (TN) and epidermal growth factor 2 (HER2)-positive breast cancer (BC) patients, and currently, there is an unmet need for the treatment of these pa...
Source: Molecular Cancer - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
The FDA granted a priority review to a new drug application submitted by Seattle Genetics, Inc. for tucatinib to treat patients with HER2-positive breast cancer.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
Abstract BACKGROUND: Although inflammatory breast cancer (IBC) is postulated to be a distinct biological entity, practice guidelines and previous data suggest that treatment and outcomes are influenced by standard approximated biological subtype. The aim of this study was validation in a large recent National Cancer Database (NCDB) patient cohort. METHODS: Patients with non-metastatic IBC treated in 2010-2015 with neoadjuvant systemic therapy and surgery were identified from the NCDB. Approximated biological subtypes were categorized as oestrogen receptor-positive (ER+)/human epidermal growth factor receptor ...
Source: The British Journal of Surgery - Category: Surgery Authors: Tags: Br J Surg Source Type: research
Future Oncology, Ahead of Print.
Source: Future Oncology - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSION: Our study shows that receiving lapatinib with food can increase its plasma concentration with no significantly increased drug-related toxicity. We suggest that a larger-sample-size clinical trial is needed to fully understand the effect of administration of lapatinib with food. PMID: 32058619 [PubMed - as supplied by publisher]
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
ConclusionAdministration of adjuvant eribulin after neoadjuvant chemotherapy was feasible and well tolerated. The 24-month DFS rate did not reach the study target levels in any of the cohorts and was similar to DFS previously described in these cohorts following neoadjuvant chemotherapy alone.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
Condition:   Breast Cancer Intervention:   Drug: 99mTc-HPArk2 Sponsor:   Peking Union Medical College Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | Genetics | HER2 | Herceptin | Study